By Scientia Professor Vlado Perkovic

Journal articles

Enríquez AJ; Mahaffey KW; Tuttle K; Baeres FMM; Bakris G; Idorn T; Perkovic V; Rasmussen IKB; Rasmussen S; Rossing P; Sokareva E; Mann J; Pratley R, 2025, 'CO-025. RESULTADOS CARDIOVASCULARES CON SEMAGLUTIDA EN FUNCIÓN DEL ESTADO BASAL DE LA ENFERMEDAD RENAL CRÓNICA EN PARTICIPANTES CON DIABETES TIPO 2 Y ENFERMEDAD RENAL CRÓNICA: RESULTADOS DEL ENSAYO FLOW', Endocrinología, Diabetes y Nutrición, 72, pp. 15 - 15, http://dx.doi.org/10.1016/s2530-0164(25)00132-6

Soveri I; Mann JF; Pratley RE; Schmieder RE; Cherney D; MacIsaac RJ; Rossing P; Mahaffey KW; L S; Bellary S; Perkovic V; Lim SK; Gumprecht J; Belmar N; Bosch-Traberg H; Rasmussen S; Tuttle KR; Charytan DM, 2025, 'Discordance Between Cystatin C-Based eGFR and Creatinine-Based eGFR and Cardiovascular Risk in the FLOW Trial', Journal of the American Society of Nephrology, 36, http://dx.doi.org/10.1681/asn.2025jg5nr2bm

Barratt J; Rizk D; Zhang H; Maes B; Kashihara N; Rovin B; Trimarchi H; Kollins D; Desai M; Papachristofi O; Koukouli E; Perkovic V, 2025, 'Effect of iptacopan discontinuation on proteinuria and complement biomarkers in patients with immunoglobulin A nephropathy (IgAN): a post hoc analysis from a Phase II trial', NEPHROLOGY DIALYSIS TRANSPLANTATION, 40, http://dx.doi.org/10.1093/ndt/gfaf116.030

Mann JF; Badve S; Baeres FMM; Belmar N; Brown-Frandsen KS; Buse J; Colhoun H; Deanfield J; Engelmann MDM; Hovingh K; Idorn T; Lincoff AM; Lingvay I; Mahaffey KW; McGuire DK; Pratley RE; Rasmussen S; Rossing P; Sattar N; Tuttle KR; Perkovic V, 2025, 'Effect of Semaglutide on Kidney Outcomes: Pooled Analysis of the SELECT, FLOW, and SOUL Trials', Journal of the American Society of Nephrology, 36, http://dx.doi.org/10.1681/asn.2025vd9epqq7

Zhang H; Perkovic V; Barratt J; Rizk DV; Rovin B; Trimarchi H; Maes BD; Merkel T; Desai MM; Ansari S; Hach T; Renfurm R; Kashihara N, 2025, 'Efficacy and Safety of Iptacopan in Patients (Pts) from East Asia with IgAN: Interim Results from the Phase 3 APPLAUSE-IgAN Trial', Journal of the American Society of Nephrology, 36, http://dx.doi.org/10.1681/asn.2025bmx8dwvd

L S; Arici M; Bax WA; Busch RS; Correa-Rotter R; Gorriz JL; Gumprecht J; Idorn T; Mahaffey KW; Mann JF; Mayrdorfer M; Baastrup Nordsborg R; Pratley RE; Pugliese G; Rasmussen DGK; Rossing P; Tangri N; Tuttle KR; Perkovic V, 2025, 'FLOW: Effects of Semaglutide on Kidney Failure Using the Kidney Failure Risk Equation', Journal of the American Society of Nephrology, 36, http://dx.doi.org/10.1681/asn.20257qtjpx6z

Kotwal SS; Jeyaruban AS; Bose B; Lee VWS; Jardine M; Mallawaarachchi A; Ritchie AG; Wong MG; Makris A; Badve S; Siriwardana A; Yong K; Perkovic V, 2025, 'Glomerular Disease Registry and Biobank: Baseline and Follow-Up Results', Journal of the American Society of Nephrology, 36, http://dx.doi.org/10.1681/asn.2025a2e9nynn

Neuen BL; Fletcher RA; Perkovic V; Heerspink HJL, 2025, 'Impact of Glomerular Filtration Rate and Albuminuria on the Effects of SGLT2 Inhibitors on Kidney Outcomes', Journal of the American Society of Nephrology, 36, http://dx.doi.org/10.1681/asn.2025bs338s8x

Zhang H; Perkovic V; Barratt J; Rizk DV; Rovin B; Trimarchi H; Maes B; Merkel T; Desai M; Ansari S; Renfurm R; Hach T; Kashihara N, 2025, 'Iptacopan in Patients With IgA Nephropathy From East Asia', Kidney International Reports, http://dx.doi.org/10.1016/j.ekir.2025.10.017

Varas IJ; Perkovic V; Tuttle KR; Rossing P; Mahaffey KW; Mann J; Bakris G; Baeres FM; Idorn T; Bosch-Traberg H; Lausvig NL; Pratley R, 2025, 'P-190. ENSAYO FLOW: EFECTO DE SEMAGLUTIDA EN PERSONAS CON ENFERMEDAD RENAL CRÓNICA Y DIABETES TIPO 2', Endocrinología, Diabetes y Nutrición, 72, pp. 76 - 77, http://dx.doi.org/10.1016/s2530-0164(25)00253-8

Heerspink HJL; Pecoits-Filho R; Ambery PD; Adamsson Eryd S; Lesén E; Nam Y-S; Thuresson M; Perkovic V, 2025, 'Risk of CKD Progression in a Real-World Population Eligible for the ZENITH-High Proteinuria Trial', Journal of the American Society of Nephrology, 36, http://dx.doi.org/10.1681/asn.2025kp13gres

Kim D; Woodward M; Lv J; Hladunewich M; Jha V; Hooi LS; Monaghan H; Perkovic V; Zhang H; Wong MG, 2025, 'Sex differences across treatment response to corticosteroids and kidney outcomes in IgA nephropathy: insights from the TESTING trial', NEPHROLOGY DIALYSIS TRANSPLANTATION, 40, http://dx.doi.org/10.1093/ndt/gfaf116.0351

Perkovic V; Barratt J; Lafayette RA; Liew A; Suzuki Y; Carroll K; Cheung CK; Tesar V; Trimarchi H; Wong MG; Zhang H; Xia J; Fajardo C; Shah LN; Hafkin J; Rizk DV, 2025, 'Sibeprenlimab for the Treatment of IgAN: VISIONARY Phase 3 Interim and Prespecified Subgroup Analyses', Journal of the American Society of Nephrology, 36, http://dx.doi.org/10.1681/asn.20252v4ch0af

Odler B; Riedl R; Geetha D; Szpirt WM; Hawley C; Uchida L; Wallace ZS; Walters G; Muso E; Tesar V; Pusey CD; Little MA; Merkel PA; Walsh M; Jayne DRW; Kronbichler A; PEXIVAS Investigators , 2025, 'The effects of plasma exchange and glucocorticoids on early kidney function among patients with ANCA-associated vasculitis in the PEXIVAS trial.', Kidney Int, 107, pp. 558 - 567, http://dx.doi.org/10.1016/j.kint.2024.11.029

Kotwal S; Jeyaruban A; Bose B; Lee V; Jardine M; MALLAWARCHCHI A; Ritchie A; Wong M-G; Makris A; Badve S; Siriwardana A; Yong K; Perkovic V, 2025, 'WCN25-1567 Glomerular disease registry and Biobank (GRIT)– design and baseline results', Kidney International Reports, 10, pp. S196 - S197, http://dx.doi.org/10.1016/j.ekir.2024.11.382

Kotwal S; Perkovic V; Jardine M; Vart P; Wheeler D; de Boer I; Zhang H; Hou FF; Sugawara Y; De Nicola L; Gorriz J; Heerspink H, 2025, 'WCN25-1572 DESIGN AND BASELINE CHARACTERISTICS OF THE GLOBAL KIDNEY PATIENT TRIALS NETWORK', Kidney International Reports, 10, pp. S287 - S288, http://dx.doi.org/10.1016/j.ekir.2024.11.535

Tuttle K; Arici M; Arslan EG; Bellary S; Idorn T; Ji L; Kamenov Z; Kashihara N; Mann J; Mahaffey K; Perkovic V; Rasmussen S; Rossing P; Schytz PA; Sreenivasamurthy L; Pratley R, 2025, 'WCN25-1900 Clinical and Safety Outcomes of Semaglutide by CKD Severity in the FLOW trial', Kidney International Reports, 10, pp. S770 - S770, http://dx.doi.org/10.1016/j.ekir.2024.11.1358

Lafayette R; Trimarchi H; Barratt J; Carroll K; Tesar V; Zhang H; Suzuki Y; Liew A; Wong MG; Shah L; Xia J; Fajaro C; Hafkin J; Perkovic V, 2025, 'WCN25-499 PATIENT BASELINE CHARACTERISTICS IN THE ONGOING PHASE 3 VISIONARY TRIAL: A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF SIBEPRENLIMAB FOR IMMUNOGLOBULIN A NEPHROPATHY', Kidney International Reports, 10, pp. S158 - S159, http://dx.doi.org/10.1016/j.ekir.2024.11.328

Rizk D; Lafayette R; Trimarchi H; Barratt J; Carroll K; Tesar V; Zhang H; Suzuki Y; Liew A; Wong MG; Shah L; Xia J; Fajaro C; Hafkin J; Perkovic V, 2025, 'WCN25-499 PATIENT BASELINE CHARACTERISTICS IN THE ONGOING PHASE 3 VISIONARY TRIAL: A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF SIBEPRENLIMAB FOR IMMUNOGLOBULIN A NEPHROPATHY (vol 10, pg S158, 2025)', KIDNEY INTERNATIONAL REPORTS, 10, pp. 2892 - 2892

Kollins D; Papachristofi O; Hach T; Valentin M-A; Merkel T; Renfurm R; Perkovic V, 2025, 'WCN25-716 EFFECT OF IPTACOPAN ON PROTEINURIA AND COMPLEMENT BIOMARKERS IN IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE PHASE 3 APPLAUSE-IgAN STUDY', Kidney International Reports, 10, pp. S177 - S177, http://dx.doi.org/10.1016/j.ekir.2024.11.358

Perkovic V; Rizk D; Kollins D; Papachristofi O; Hach T; Valentin M-A; Merkel T; Renfurm R, 2025, 'WCN25-716 EFFECT OF IPTACOPAN ON PROTEINURIA AND COMPLEMENT BIOMARKERS IN IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE PHASE 3 APPLAUSE-IgAN STUDY (vol 10, pg S177, 2025)', KIDNEY INTERNATIONAL REPORTS, 10, pp. 2890 - 2890

Kollins D; Papachristofi O; Hach T; Jacinto-Sanders S; Merkel T; Schmouder R; Kulmatycki K; Renfurm R; Perkovic V, 2025, 'WCN25-797 SAFETY AND EFFICACY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN) WITH BASELINE eGFR 20-<30 mL/MIN: PHASE 3 APPLAUSE-IgAN SUBCOHORT RESULTS', Kidney International Reports, 10, pp. S183 - S184, http://dx.doi.org/10.1016/j.ekir.2024.11.362

Perkovic V; Rizk D; Kollins D; Papachristo O; Hach T; Jacinto-Sanders S; Merkel T; Schmouder R; Kulmatycki K; Renfurm R, 2025, 'WCN25-797 SAFETY AND EFFICACY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN) WITH BASELINE eGFR 20-<30 mL/MIN: PHASE 3 APPLAUSE-IgAN SUBCOHORT RESULTS (vol 10, pg S183, 2025)', KIDNEY INTERNATIONAL REPORTS, 10, pp. 2890 - 2890

Kollins D; Papachristofi O; Hach T; Jacinto-Sanders S; Merkel T; Renfurm R; Perkovic V, 2025, 'WCN25-799 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS (IA) OF THE PHASE 3 APPLAUSE-IgAN STUDY', Kidney International Reports, 10, pp. S184 - S184, http://dx.doi.org/10.1016/j.ekir.2024.11.363

Rizk D; Kollins D; Papachristo O; Hach T; Jacinto-Sanders S; Merkel T; Renfurm R; Perkovic V, 2025, 'WCN25-799 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS (IA) OF THE PHASE 3 APPLAUSE-IgAN STUDY( vol 10, pg S184 , 2025)', KIDNEY INTERNATIONAL REPORTS, 10, pp. 2890 - 2890

Perkovic V; Tuttle K; Sattar N; Lincoff AM; Navar AM; Marx N; Hvelplund A; Baeres FMM; Engelmann MD; Hovingh GK; Ridker PM, 2025, 'WCN25-888 DESIGN OF THE ZEUS TRIAL: INTERLEUKIN 6 INHIBITION WITH ZILTIVEKIMAB FOR CARDIOVASCULAR PROTECTION IN CHRONIC KIDNEY DISEASE', Kidney International Reports, 10, pp. S767 - S768, http://dx.doi.org/10.1016/j.ekir.2024.11.1354

Kotwal SS; Perkovic V; Jardine MJ; Kim D; Shah NA; Lin E; Coggan S; Billot L; Vart P; Wheeler DC; De Boer IH; Zhang H; Hou FF; Sugawara Y; Marion J; Lewis RJ; Berry LR; McGlothlin A; Jha V; De Nicola L; Gorriz JL; Heerspink HJL, 2024, 'The Global Kidney Patient Trials Network and the CAPTIVATE Platform Clinical Trial Design: A Trial Protocol', JAMA Network Open, 7, http://dx.doi.org/10.1001/jamanetworkopen.2024.49998

Heerspink HJL; Perkovic V; Tuttle KR; Pergola PE; Mahaffey KW; Patel UD; Ishida JH; Kuo A; Chen F; Kustra R; Petrovic V; Rossing P; Kashihara N; Chertow GM, 2024, 'Selonsertib in Patients with Diabetic Kidney Disease: A Phase 2b Randomized Active Run-In Clinical Trial', Journal of the American Society of Nephrology, 35, pp. 1726 - 1736, http://dx.doi.org/10.1681/ASN.0000000000000444

Neuen BL; Ostrominski JW; Claggett B; Beldhuis IE; Chatur S; McCausland FR; Badve SV; Arnott C; Heerspink HJL; Jun M; Falster M; de Oliveira Costa J; Pollock C; Jardine MJ; Mahaffey KW; Perkovic V; Solomon SD; Vaduganathan M, 2024, 'Bidirectional Relationship Between Kidney Disease Progression and Cardiovascular Events in Type 2 Diabetes', Journal of the American College of Cardiology, 84, pp. 2246 - 2250, http://dx.doi.org/10.1016/j.jacc.2024.08.006

Neuen BL; Fletcher RA; Heath L; Perkovic A; Vaduganathan M; Badve SV; Tuttle KR; Pratley R; Gerstein HC; Perkovic V; Heerspink HJL, 2024, 'Cardiovascular, Kidney, and Safety Outcomes with GLP-1 Receptor Agonists Alone and in Combination with SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis', Circulation, 150, pp. 1781 - 1790, http://dx.doi.org/10.1161/CIRCULATIONAHA.124.071689

Perkovic V; Tuttle KR; Pratley R, 2024, 'The authors reply: Semaglutide for Chronic Kidney Disease in Type 2 Diabetes', New England Journal of Medicine, 391, pp. 1757, http://dx.doi.org/10.1056/NEJMc2410532

Neuen BL; Ostrominski JW; Claggett BL; Beldhuis I; Chatur S; Arnott C; Heerspink HJL; Pollock C; Jardine M; Mahaffey KW; Perkovic V; Solomon SD; Vaduganathan M, 2024, 'Bidirectional relationship between kidney disease progression and cardiovascular events in type 2 diabetes: new Insights from the CANVAS Program and CREDENCE trial', EUROPEAN HEART JOURNAL, 45, http://dx.doi.org/10.1093/eurheartj/ehae666.3264

Chatur S; Neuen BL; Fletcher RA; Perkovic V; Heerspink H; Arnott C; Pollock C; Mahaffey KW; Neal B; Jardine M; Solomon SD; Vaduganathan M, 2024, 'Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: a participant level pooled analysis of CREDENCE and CANVAS', European Heart Journal, 45, pp. ehae666.1228, http://dx.doi.org/10.1093/eurheartj/ehae666.1228

Pratley RE; Tuttle KR; Rossing P; Rasmussen S; Perkovic V; Nielsen OW; Mann JFE; MacIsaac RJ; Kosiborod MN; Kamenov Z; Idorn T; Hansen MB; Hadjadj S; Bakris G; Baeres FMM; Mahaffey KW, 2024, 'Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial', Journal of the American College of Cardiology, 84, pp. 1615 - 1628, http://dx.doi.org/10.1016/j.jacc.2024.08.004

Li J; Lv J; Wong MG; Shi S; Zan J; Monaghan H; Perkovic V; Zhang H; Agarwal R; Barbour S; Cattran D; Cass A; Chan TM; Feehally J; Glassock R; Hladunewich MA; Hooi LS; Jardine MJ; Jha V; Johnson DW; Levin A; Liu ZH; Reich H; Remuzzi G; Wheeler DC; Wong MG; Woodward M; Wu Y; Zhao M, 2024, 'Correlation of Urinary Soluble CD163 Levels With Disease Activity and Treatment Response in IgA Nephropathy', Kidney International Reports, 9, pp. 3016 - 3026, http://dx.doi.org/10.1016/j.ekir.2024.07.031

Mann JFE; Rossing P; Bakris G; Belmar N; Bosch-Traberg H; Busch R; Charytan DM; Hadjadj S; Gillard P; Górriz JL; Idorn T; Ji L; Mahaffey KW; Perkovic V; Rasmussen S; Schmieder RE; Pratley RE; Tuttle KR, 2024, 'Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial', Nature Medicine, 30, pp. 2849 - 2856, http://dx.doi.org/10.1038/s41591-024-03133-0

Kotwal SS; Dip G; Perkovic V, 2024, 'Kidney Disease as a Cardiovascular Disease Priority', Circulation, 150, pp. 975 - 977, http://dx.doi.org/10.1161/CIRCULATIONAHA.124.068242

Vaduganathan M; Cannon CP; Jardine MJ; Heerspink HJL; Arnott C; Neuen BL; Sarraju A; Gogate J; Seufert J; Neal B; Perkovic V; Mahaffey KW; Kosiborod MN, 2024, 'Effects of canagliflozin on total heart failure events across the kidney function spectrum: Participant-level pooled analysis from the CANVAS Program and CREDENCE trial', European Journal of Heart Failure, 26, pp. 1967 - 1975, http://dx.doi.org/10.1002/ejhf.3292

Fletcher RA; Herrington WG; Agarwal R; Mayne KJ; Arnott C; Jardine MJ; Mahaffey KW; Perkovic V; Staplin N; Wheeler DC; Chertow GM; Heerspink HJL; Neuen BL, 2024, 'Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cause-Specific Cardiovascular Death in Patients with CKD A Meta-Analysis of CKD Progression Trials', Clinical Journal of the American Society of Nephrology, 19, pp. 1180 - 1182, http://dx.doi.org/10.2215/CJN.0000000000000470

Cardoza K; Kang A; Smyth B; Yi TW; Pollock C; Agarwal R; Bakris G; Charytan DM; de Zeeuw D; Wheeler DC; Zhang H; Cannon CP; Perkovic V; Arnott C; Levin A; Mahaffey KW, 2024, 'Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trial', Diabetes Obesity and Metabolism, 26, pp. 3530 - 3540, http://dx.doi.org/10.1111/dom.15685

Ha JT; Hiremath S; Jun M; Green SC; Wheeler DC; Coyne DW; Perkovic V; Badve SV, 2024, 'Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Kidney Disease', Nejm Evidence, 3, http://dx.doi.org/10.1056/EVIDoa2300189

Junek ML; Merkel PA; Vilayur E; Wald R; Khalidi N; Jayne D; Walsh M; Paizis K; Reidlinger D; Morrish A; Badve SV; Pascoe E; Paul-Brent PA; Robison L; Valks A; Walters G; Jardine M; Milton C; Ibraham A; Siva B; Desmond M; Perkovic V; Kurtkoti J; Cass A; Summers S; Brown F; Ryan J; Kerr P; Noble E; Luxton G; Mudge DW; Hawley C; Johnson DW; Peh CA; Faull RJ; Ranganathan D; Jeffs L; Nicholls K; Hughes P; Cooper B; Boudville N; Ford S; Langham R; Blockmans D; Henckaerts L; Sprangers B; Suri R; Brachemi S; Clark W; Garg A; Carette S; Pagnoux C; Reich H; Barth D; Walsh M; Cox G; Mazzetti A; Robins D; Perl J; Pavenski K; Dacouris N; Levin A; Copland M; Fairhead T; Pannu N; Qarni MU; Habib S; Girard L; Manns B; Tesar V; Hruskova Z; Chocova Z; Povlsen J; Gregersen J; Ivarsen P; Birn H; Krarup E; Pedersen EB; Thomsen I; Bech JN; Szpirt W; Egfjord M; Mesbah R; Bataille P; Rey I; Gombert B; Chantrel F; Vanhille P; Quémeneur T; Carron PL; Zaoui P; de Moreuil C; Gosselin M; Delluc A; Hanrotel-Saliou C; Le Jeune M; Ficheux M, 2024, 'Risk of Relapse of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis in a Randomized Controlled Trial of Plasma Exchange and Glucocorticoids', Arthritis and Rheumatology, 76, pp. 1431 - 1438, http://dx.doi.org/10.1002/art.42843

Apperloo EM; Neuen BL; Fletcher RA; Jongs N; Anker SD; Bhatt DL; Butler J; Cherney DZI; Herrington WG; Inzucchi SE; Jardine MJ; Liu CC; Mahaffey KW; McGuire DK; McMurray JJV; Neal B; Packer M; Perkovic V; Sabatine MS; Solomon SD; Staplin N; Szarek M; Vaduganathan M; Wanner C; Wheeler DC; Wiviott SD; Zannad F; Heerspink HJL, 2024, 'Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials', Lancet Diabetes and Endocrinology, 12, pp. 545 - 557, http://dx.doi.org/10.1016/S2213-8587(24)00155-4

Tangri N; Ferguson TW; Bamforth RJ; Leon SJ; Arnott C; Mahaffey KW; Kotwal S; Heerspink HJL; Perkovic V; Fletcher RA; Neuen BL, 2024, 'Machine learning for prediction of chronic kidney disease progression: Validation of the Klinrisk model in the CANVAS Program and CREDENCE trial', Diabetes Obesity and Metabolism, 26, pp. 3371 - 3380, http://dx.doi.org/10.1111/dom.15678

Neuen BL; Claggett BL; Perkovic V; Jardine M; Heerspink HJL; Mahaffey KW; McMurray JJV; Solomon SD; Vaduganathan M, 2024, 'Timing of Cardio-Kidney Protection With SGLT2 Inhibitors: Insights From 4 Large-Scale Placebo-Controlled Outcome Trials', Circulation, 150, pp. 343 - 345, http://dx.doi.org/10.1161/CIRCULATIONAHA.124.069382

Perkovic V; Tuttle KR; Rossing P; Mahaffey KW; Mann JFE; Bakris G; Baeres FMM; Idorn T; Bosch-Traberg H; Lausvig NL; Pratley R, 2024, 'Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes', New England Journal of Medicine, 391, pp. 109 - 121, http://dx.doi.org/10.1056/NEJMoa2403347

Kim D; Lv J; Hladunewich M; Jha V; Hooi LS; Monaghan H; Shan S; Reich HN; Barbour S; Billot L; Zhang H; Perkovic V; Wong MG; Levin A; Cattran D; Johnson DW; Wheeler D; Flöge J; Woodward M; Jardine M; Zhao MH; Agarwal R; Glassock R; Chan TM; Wu Y; Liu Z, 2024, 'The Efficacy and Safety of Reduced-Dose Oral Methylprednisolone in High-Risk Immunoglobulin A Nephropathy', Kidney International Reports, 9, pp. 2168 - 2179, http://dx.doi.org/10.1016/j.ekir.2024.03.032

Patel SM; Kang YM; Im KA; Neuen BL; Anker SD; Bhatt DL; Butler J; Cherney DZI; Claggett BL; Fletcher RA; Herrington WG; Inzucchi SE; Jardine MJ; Mahaffey KW; McGuire DK; McMurray JJV; Neal B; Packer M; Perkovic V; Solomon SD; Staplin N; Vaduganathan M; Wanner C; Wheeler DC; Zannad F; Zhao Y; Heerspink HJL; Sabatine MS; Wiviott SD, 2024, 'Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis', Circulation, 149, pp. 1789 - 1801, http://dx.doi.org/10.1161/CIRCULATIONAHA.124.069568

Fussner LA; Flores-Suárez LF; Cartin-Ceba R; Specks U; Cox PG; Jayne DRW; Merkel PA; Walsh M; Paizis K; Walters G; Jardine M; Milton C; Ibraham A; Siva B; Desmond M; Perkovic V; Kurtkoti J; Vilayur E; Cass A; Summers S; Brown F; Ryan J; Kerr P; Noble E; Luxton G; Mudge DW; Hawley C; Johnson DW; Peh CA; Faull RJ; Ranganathan D; Jeffs L; Nicholls K; Hughes P; Cooper B; Boudville N; Ford S; Langham R; Reidlinger D; Morrish A; Badve SV; Pascoe E; Paul-Brent PA; Robison L; Valks A; Blockmans D; Henckaerts L; Sprangers B; Suri R; Brachemi S; Clark W; Garg A; Carette S; Pagnoux C; Reich H; Barth D; Khalidi N; Cox G; Mazzetti A; Robins D; Wald R; Perl J; Pavenski K; Dacouris N; Levin A; Copland M; Fairhead T; Pannu N; Qarni MU; Habib S; Girard L; Manns B; Tesar V; Hruskova Z; Chocova Z; Povlsen J; Gregersen J; Ivarsen P; Birn H; Krarup E; Pedersen EB; Thomsen I; Bech JN; Szpirt W; Egfjord M; Mesbah R; Bataille P; Rey I; Chantrel F; Vanhille P; Quémeneur T; Carron PL; Zaoui P; de Moreuil C; Gosselin M; Delluc A; Hanrotel-Saliou C; Le Jeune M; Ficheux M; Aniort J, 2024, 'Alveolar Hemorrhage in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Results of an International Randomized Controlled Trial (PEXIVAS)', American Journal of Respiratory and Critical Care Medicine, 209, pp. 1141 - 1151, http://dx.doi.org/10.1164/rccm.202308-1426OC

Heerspink HJL; Stack AG; Terkeltaub R; Jongs N; Inker LA; Bjursell M; Maklad N; Perl S; Eklund O; Rikte T; Sjöström CD; Perkovic V; Chmelickova H; Lukac M; Bucek P; Drasnar T; Dussol B; Guerrot D; Legrand E; Boffa JJ; Halimi JM; Zaoui P; Letoha A; Hajdu C; Pall D; Peterfai E; Csécsei G; Bezzegh K; Deak L; Konyves L; Zsom M; Danos P; Vangel S; Vasas S; Oroszlan T; Zilahi Z; Leiba A; Grossman A; Leibowitz A; Itzhak B; Daoud D; Farber E; Adawi F; Nakhoul FM; Chernin G; Kenis I; Wainstein J; Zeller L; Elias M; Atar S; Frajewicki V; Yagil Y; Armaly ZA; Esposito C; Viazzi F; Gambaro G; Piatti P; Bonadonna RC; Arias Delgadillo CR; Flores FJ; Aguilera Real ME; Fajardo-Campos P; Violante Ortiz RM; Luna Ceballos RI; Duran-Barragan S; Zytkiewicz-Jaruga D; Krzyzagorska E; Skokowska E; Klodawska K; Mordaka R; Mazur S; Stasinska T; Sulowicz W; Constantin C; Negru D; Paveliu FS; Negrisanu GD; Szilagyi I; Busegeanu MMG; Pena MC; Avram RI; Ardelean SL; Ilavska A; Dzupina A; Oroszova A; Kolesarova E; Obetkova I; Smatanova I; Babikova J; Fulop P; Haffner R; Rayner BL; Kruger DS; Urbach DV; Mitha E; Vally Mahomed Latiff GH; Makan H; Du Plessis H; Jurgens JC; Reddy J, 2024, 'Combination Treatment with Verinurad and Allopurinol in CKD: A Randomized Placebo and Active Controlled Trial', Journal of the American Society of Nephrology, 35, pp. 594 - 606, http://dx.doi.org/10.1681/ASN.0000000000000326

Back to profile page